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paOBJECTIVES This study sought to compare the per-patient diagnostic performance of coronary computed tomography
angiography (CTA)-derived fractional flow reserve (FFRCT) with that of single-photon emission computed tomography
(SPECT), using a fractional flow reserve (FFR) value of #0.80 as the reference for diagnosing at least 1 hemodynamically
significant stenosis in a head-to-head comparison of patients with intermediate coronary stenosis as determined by
coronary CTA.
BACKGROUND No previous study has prospectively compared the diagnostic performance of FFRCT and myocardial
perfusion imaging by SPECT in symptomatic patients with intermediate range coronary artery disease (CAD).
METHODS This study was conducted at a single-center as a prospective study in patients with stable angina pectoris
(N ¼ 143). FFRCT and SPECT analyses were performed by core laboratories and were blinded for the personnel responsible
for downstream patient management. FFRCT #0.80 distally in at least 1 coronary artery with a diameter$2 mm classified
patients as having ischemia. Ischemia by SPECT was encountered if a reversible perfusion defect (summed difference
score $2) or transitory ischemic dilation of the left ventricle (ratio >1.19) were found.
RESULTS The per-patient diagnostic performance for identifying ischemia (95% confidence interval [CI]), FFRCT versus
SPECT, were sensitivity of 91% (95% CI: 81% to 97%) versus 41% (95% CI: 29% to 55%; p < 0.001); specificity of 55%
(95% CI: 44% to 66%) versus 86% (95% CI: 77% to 93%; p < 0.001); negative predictive value of 90% (95% CI: 82%
to 98%) versus 68% (95% CI: 59% to 77%; p ¼ 0.001); positive predictive value of 58% (95% CI: 48% to 68%)
versus 67% (95% CI: 51% to 82%; p ¼ NS); and accuracy of 70% (95% CI: 62% to 77%) versus 68% (95% CI: 60% to
75%; p ¼ NS) respectively.
CONCLUSIONS In patients with stable chest pain and CAD as determined by coronary CTA, the overall diagnostic
accuracy levels of FFRCT and SPECT were identical in assessing hemodynamically significant stenosis. However,
FFRCT demonstrated a significantly higher diagnostic sensitivity than SPECT. (J Am Coll Cardiol Img 2018;11:1640–50)
© 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 1936-878X https://doi.org/10.1016/j.jcmg.2018.05.004
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ABBR EV I A T I ON S
AND ACRONYMS
CAD = coronary artery disease
CTA = computed tomography
angiography
CX = circumflex coronary artery
FFR = fractional flow reserve
FFRCT = coronary CTA-derived
fractional flow reserve
LAD = left anterior descending
coronary artery
MPI = myocardial perfusion
imaging
RCA = right coronary artery
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1641I n patients with suspected stable coronary arterydisease (CAD), myocardial perfusion imaging(MPI) provides high diagnostic performance for
identifying regional differences in myocardial blood
flow supply when compared with coronary anatomy,
and a normal MPI result has been associated with
favorable clinical outcomes (1). Therefore, current
guidelines recommend MPI as the frontline testing
strategy in symptomatic patients with intermediate
risk of CAD (2,3). Single-photon emission computed
tomography (SPECT) is the diagnostic method most
commonly used in patients with stable CAD (4),
despite reports of a merely modest diagnostic sensi-
tivity in high-risk subgroups (5) and inaccuracies
in the selection of patients to undergo invasive coro-
nary angiography (ICA) (6). Accordingly, coronary
computed tomography angiography (CTA) has evolved
as an alternative frontline testing strategy due to high
diagnostic performance for detection and exclusion of
CAD (7). However, the hemodynamic significance of le-
sions cannot be assessed by coronary CTA. Thus, guide-
lines recommend additional functional testing to be
performed in patients with significant CAD determined
by coronary CTA to increase appropriateness of referral
to coronary angiography (3).SEE PAGE 1651Recently, improvements in computational fluid
dynamics and individual image-based modeling have
allowed estimation of coronary blood flow and pres-
sure from standard acquired coronary CTA datasets
(8). Coronary CTA-derived fractional flow reserve
(FFRCT) has shown high diagnostic performance, us-
ing measured fractional flow reserve (FFR) as the
reference standard (9). Compared with coronary CTA
assessment alone, FFRCT demonstrates improved
discrimination of ischemia (10), and FFRCT utility in
clinical practice has been demonstrated by safe
reduction of downstream invasive angiography
compared to that of usual care (11), as well as
improvement of the diagnostic yield of coronary
angiography (12). The value of FFRCT versus that of
SPECT as a gatekeeper to coronary angiography in
patients with CAD determined by coronary CTA has
not previously been prospectively assessed. There-
fore, the aim of this study was to compare FFRCT with
MPI by SPECT in consecutive symptomatic patientsEdwards LifeSciences, and HeartFlow. Dr. Jensen has received institutiona
and Biotronik. All other authors have reported that they have no rela
to disclose.
Manuscript received March 23, 2018; revised manuscript received May 4, 20suspected of having obstructive CAD as
determined by coronary CTA.
METHODS
STUDY DESIGN AND PATIENT COHORT. This
was a prospective study designed to compare
the diagnostic performance of FFRCT with
that of SPECT for, first, the diagnosis of at
least 1 hemodynamically significant stenosis,
using measured FFR as the reference, and
second, the prediction of standard-of-care–
guided coronary revascularization.
In Denmark, coronary CTA has emerged as
the preferred nonemergent testing strategy
in patients with new onset stable chest pain
in many centers. Generally, patients with a
low-to-intermediate pre-test risk of having
significant CAD, with no prior revasculariza-
tion, with a body mass index #40 kg/m2, with a
glomerular filtration rate $45 ml/min, and no
persistent atrial fibrillation are eligible for coronary
CTA. Consequently, clinical criteria for inclusion in
this study were stable chest pain in patients without
known CAD and a Diamond-Forrester risk score be-
tween 15% and 85%. Moreover, study inclusion
required the presence of at least 1 coronary stenosis of
40% to 90%, as determined by coronary CTA, or 1 or
more focal lesions with severe calcification compro-
mising stenosis assessment. Exclusion criteria were
known CAD or a summed Agatston score $1,000 U.
Patients with inability to undergo adenosine testing,
allergy to iodinated contrast media, noncardiac
illness with life expectancy <2 years, or pregnancy
were excluded. Patients were included prior to func-
tional testing. All CT data underwent FFRCT analysis,
and all patients underwent SPECT perfusion imaging
and invasive procedures performed as illustrated in
Figure 1. All patients were referred to ICA per-
protocol, and the physicians responsible for down-
stream patient management were blinded to results
of FFRCT and SPECT analyses, including those who
were performing the ICA and FFR investigations.
FFRCT and SPECT assessments were performed at
core laboratories by personnel who had information
about the lesion(s) of interest by coronary CTA;
otherwise, the laboratory staff was blinded to clinical
data. Patients were thoroughly instructed to stopl research grants from St. Jude Medical, Biosensors,
tionships relevant to the contents of this paper
18, accepted May 9, 2018.
FIGURE 1 Schematic Illustration of the Study Protocol
FFRCT (Core Lab)









IV adenosine 140 mcg/kg/min
Positive: FFR ≤0.80
SPECT perfusion imaging and FFRCT analysis were performed at core laboratories be-
tween the time of the coronary CTA examination and the invasive procedure. The results
of core laboratory FFRCT analysis and SPECT test assessments had no impact on referral to
invasive angiography and were blinded to the interventionalists. CAC ¼ coronary artery
calcification; CTA ¼ computed tomography angiography; FFRCT ¼ fractional flow
reserve derived from coronary computed tomography angiography; SDS ¼ summed
difference score; SPECT ¼ single-photon computed tomography angiography;
TID ¼ transient ischemic dilation.
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1642ingestion of caffeine for 24 h prior to undergoing
SPECT and invasive procedures. Coronary angiog-
raphy was performed in all patients, with measure-
ment of FFR in lesions of interest as outlined by a CT
cardiologist. Inconclusive noninvasive test results
were registered as positive for ischemia. Informed
consent was obtained from all participants. The study
was approved by the regional ethical committee of
Southern Denmark (S-20150085) and the data pro-
tection registry of Southern Denmark (2008-58-0035;
1563).
CORONARY CTA. Coronary CTA was performed using
either a SOMATOM Definition Flash or a FORCE CT
scanner (both from Siemens, Forchheim, Germany).
Oral beta-blockers or ivabradine was administered, if
necessary, targeting a heart rate #60 beats/min. All
patients received sublingual nitroglycerin. An initial
nonenhanced scan for calcium scoring was per-
formed. Coronary CTA was assessed by skilled
CT cardiologists (all having more than 10 years of
experience in coronary CTA interpretation). Vessels
$2 mm in diameter were evaluated and graded
visually by the interpreters. Location of lesions was
reported using a 17-segment model (13). Lesion
locations were classified as proximal if located in
segments 1, 2, 5, 6, 7, 11, or 13; all other lesion
locations were classified as distal.
FFRCT AND ANALYSIS. Standard acquired coronary
CTA data sets were transmitted for central analysis(HeartFlow Inc., Redwood City, California) as previ-
ously described (12). The principles behind FFRCT
computation have been described in detail previously
(8). FFRCT was displayed for each point in the coro-
nary tree. Any FFRCT value in the major coronary
arteries $2 mm in diameter, including side branches,
were registered. Patients were classified as having
significant ischemia if at least 1 vessel had an
FFRCT #0.80.
SPECT. MPI was performed in accordance with soci-
ety guidelines (14) as gated SPECT by using a 2-day
stress-rest protocol. A dose of 740 MBq of
technitium-99m- labeled tetrofosmin (Myoview, GE
Healthcare, Milwaukee, Wisconsin) was timed to the
pharmacologic stress agent or injected at peak
exercise.
Adenosine-based stress studies were recom-
mended in order to simulate the scenario of vasodi-
lation in the catheterization laboratory and
assumptions of vascular reactions to adenosine.
Imaging was performed using a Discovery NM/CT
670 imaging system (GE Healthcare) 30 to 60 min
after injection during stress and 60 min after injection
at rest. Images were acquired by gated SPECT in a
64  64 matrix, using a low-energy high resolution
collimator. Gating was performed in 8 time bins. Im-
ages were corrected for attenuation. All SPECT
studies were performed at the Hospital of Southwest
Denmark. Anonymized datasets were sent to the
SPECT core laboratory (Department of Nuclear Medi-
cine, Odense University Hospital, Denmark). SPECT
studies were analyzed by 2 expert nuclear readers
(S.S.N., A.J.), using gated and ungated short axes,
horizontal and vertical long-axis myocardial tomo-
grams, and a bull’s eye-pattern plot (15). Perfusion
was graded using a 5-point scale (0 to 4) in each of 20
segments. Summed rest scores, summed stress
scores, and summed difference scores (SDS) were
recorded for each patient. Reversible defects were
graded as small if SDS was 2 to 4; moderate if SDS was
5 to 8; or large if SDS was >8. Study subjects were
categorized as having ischemia if more than 1 of the
following criteria was present: SDS was $2 and/or
there was an ungated stress-and-rest volume (tran-
sitory ischemic dilation) ratio of >1.19 (16). Final
classification of studies was obtained by consensus.
CORONARY ANGIOGRAPHY AND FFR. Coronary
angiography was performed by standard techniques.
Coronary lesion severity was evaluated on-site at the
discretion of the respective interventionalist and was
categorized according to either a 50% or a 70%
threshold. Patients were categorized as having single-
vessel to 3-vessel disease by using a 17-segment
FIGURE 2 Flowchart
Included in the study, n = 160
Obtained consent, n = 1,481
Study Population, n = 143
Screened patients, n = 1,628
Normal/nonobstructive disease by coronary CTA, n = 1,237•
Severe stenosis/nonevaluable coronary CTA, n = 85•
• Patient withdrawal, n = 6
• Severe obstructive lung disease, n = 4
• Nonprotocol ICA, n = 3
• FFR not measured according to protocol, n = 3
• Alternative diagnosis discovered (PE), n = 1
Patients with a normal scan or minimal disease did not undergo any further testing.
Patients with high-risk anatomy (severe left main or 3-vessel disease) by coronary CTA
were referred to ICA. ICA ¼ invasive coronary angiography; PE ¼ pulmonary embolism;
other abbreviations as in Figure 1.
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1643model (13). Intracoronary nitroglycerin was adminis-
trated before pressure wire measurements were
made. A 0.014-inch pressure wire (Verrata pressure
wire, Volcano Phillips, San Diego, California) was
placed distal to the coronary artery lesion. Maximal
hyperemia was induced by intravenous adenosine
(140 mg/kg per min). Recordings of aortic and
distal coronary pressures were obtained by manual
pull-back during sustained hyperemia (after 2 min of
adenosine infusion). Patients were classified as
having significant ischemia if the measured FFR value
was #0.80 in at least 1 vessel.
STATISTICAL ANALYSES. Sample size calculations
were based on paired comparison of sensitivities of
FFRCT and SPECT relative to FFR reference#0.80. The
expected sensitivity of FFRCT was 0.86 (10) and that of
SPECT was 0.60 (17). The prevalence of patients with
FFR #0.80 was expected to be 30%, as an equal dis-
tribution between grades of stenosis was anticipated.
Given significance level of 0.05 and a power of 0.8,
150 patients were needed for the study. The McNemar
test was used to compare sensitivity, specificity, and
accuracy of FFRCT and SPECT. Logistic regression us-
ing robust cluster estimation was used to compare
positive predictive value (PPV) andnegative predictive
value (NPV). The Fisher exact test and chi-square test
were used for comparison of proportions as appro-
priate. Associations between proportions of patients
with an FFR value #0.80 and decreasing patient
level minimum FFRCT value and size of perfusion
defects, respectively, were tested using weighted
linear regression with robust estimation. Kendall’s tau
was used to evaluate correlations between different
RPD categories and FFR and FFRCT values.
A p value <0.05 was considered statistically
significant. All statistical analyses were performed
using Stata version 14.0 software (Stata Corp, College
Station, Texas).RESULTS
Between September 2015 and July 2017, 1,628 consec-
utive symptomatic patients were referred to undergo
coronary CTA and screened for enrollment in this
study. In 160 patients, stenosis ranged between 40%
and 90%, of whom 143 patients underwent all tests
(Figure 2). Basic characteristics of the study cohort are
shown in Table 1. Median (interquartile range [IQR])
time delay between coronary CTA and coronary
catheterization was 24 (IQR: 18 to 31) days.
CORONARY CTA. Selected preparation parameters
and coronary characteristics by CTA are presented in
Table 2.SPECT. Stress studies were performed using adeno-
sine (n¼ 139), regadenoson (n¼2), or symptom-limited
treadmill exercise testing (n ¼ 2). Overall, 32 pa-
tients (23%) had ischemia, including 26 patients
(18%) with reversible perfusion defects (RPD): 7 of
26 (27%) with small RPDs; 11 of 26 (42%) with
moderate RPDs; and 8 of 26 (31%) with large RPDs,
and 10 patients (7%) who had transitory ischemic
dilation. A combination of the 2 measurements of
ischemia was found in 4 patients (3%). In 7 pa-
tients, no side effects to adenosine (dyspnea, chest
pain, dizziness, or headache) were registered, of
whom 3 patients had signs of reversible ischemia.
FFRCT. FFRCT analysis was performed successfully in
139 patients (97%). Overall, 87 patients (63%) had
a minimum of 1 vessel with an FFRCT value #0.80.
The overall distribution of patient-level FFRCT values
is shown in Table 3.
INVASIVE PROCEDURES. Using a threshold of 50%,
there were 55 patients (38%) with single-vessel
disease, 23 patients (16%) with 2-vessel disease, and
1 patient (1%) with 3-vessel disease; using a 70%
threshold, there were 39 patients (27%) with single-
vessel disease, 8 patients (6%) 2-vessel disease, and
1 patient (1%) with 3-vessel disease.
TABLE 1 Patient Characteristics (N ¼ 143)
Demographics
Age, yrs 64  11
Males 84 (59)
Body mass index, kg/m2 27  4
Caucasian 143 (100)
Symptoms
Typical angina 47 (33)
Atypical angina 30 (21)
Nonanginal chest pain 54 (38)
Dyspnea 12 (8)
Diamond-Forrester Score, % 49 (25–69) [12–89]
Risk factors




Family history of CVD* 33 (23)
Medical therapy
Statins 67 (47)
Platelet inhibitors 66 (46)
Beta-blockers 37 (26)
Anticoagulants 4 (3)
Angiotensin inhibitors 53 (37)
Calcium antagonists 33 (23)
Diuretics 26 (18)
Peroral antidiabetics 14 (10)
Insulin 4 (3)
Values are mean  SD, n (%), or median (interquartile range) [range]. *Defined as
a family history of cardiovascular disease in a male first-degree relative before
55 years of age or in a female first-degree relative before 65 years of age.
CVD ¼ cardiovascular disease.
TABLE 3 Association Between Patient-Level Minimum FFRCT
Value and FFR (n ¼ 139)
FFRCT Range Patients FFR #0.80
$0.85 22 0 (0)
0.81–0.85 30 5 (17)
0.76–0.80 25 8 (32)
0.71–0.75 25 16 (64)
0.61–0.70 18 11 (61)
#0.60 19 16 (84)
Values are n or n (%). Test for trend p < 0.001.
FFR ¼ fractional flow reserve; FFRCT ¼ coronary computed tomography
angiography-derived fractional flow reserve.
TABLE 4 Fractional Flow Reserve and Treatment (N ¼ 143)
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1644Data for FFR measurements and patient treatment
are presented in Table 4. In 10 patients with an
FFR #0.80 (median 0.78; IQR: 0.77 to 0.79) revascu-
larization was not performed due to small vessel
dimension, vessel tortuosity, or paucity of symptomsTABLE 2 Coronary CTA (N ¼ 143)
Preparation and basic information
Nitroglycerine 143 (100)
Medication for reduction of heart rate 123 (86)
Heart rate, beats/min 55  7
Radiation dose, mSv 3.3 (2.2–5.6) [0.6–14.5]
Analysis







Nonassessable due to focal high CAC 30 (21)
Values are n (%), mean  SD, or median (interquartile range) [range].
CAC ¼ coronary artery calcification; CTA ¼ computed tomography angiography.at the time of coronary angiography. In 39 patients
(81%), the treated lesions were located proximally.
FFRCT VERSUS SPECT. The occurrence of ischemia
was significantly different between modalities for all
grades of lesion severity, as determined by coronary
CTA (Figure 3). These differences were mainly due to
underestimation of ischemia by SPECT. In patients
with FFRCT #0.80 and no signs of ischemia by SPECT
(n ¼ 61), the percentage of patients having an
FFR #0.80 was 49%, whereas the corresponding
percentage of patients having an FFR #0.80 in pa-
tients with an FFRCT $0.80 and ischemia by SPECT
(n ¼ 6) was 17% (p < 0.001).FFR #0.80 58 (41)
FFR #0.75 40 (28)
Treatment
Optimized medical treatment, FFR $ 0.80 85 (59)
Optimized medical treatment, FFR # 0.80 10 (7)
1-vessel PCI 36 (25)
2-vessel PCI 5 (4)
3-vessel PCI 1 (1)
CABG 6 (4)
Values are n (%). In 4 patients, in whom 2-vessel disease was suspected, FFR was
performed only in 1 vessel due to subocclusion of LAD (FFR value in the RCA: 0.76)
in 1 patient who subsequently underwent CABG; subocclusion of CX (FFR-value in
the LAD: 0.66) in 1 patient who subsequently underwent CABG; severe dyspnea
during measurement of FFR in the LAD (FFR value in the LAD: 0.65) with sub-
sequent 2-vessel PCI (LAD/RCA) in 1 patient; and in 1 patient who had a severe
proximal RCA lesion treated directly by PCI (FFR value in the LAD: 0.81). In 1
patient who was suspected of having 1-vessel disease, FFR was not performed due
to severe spasm during FFR measurement in the RCA (the underlying coronary
stenosis was deemed nonsignificant, and the patient was treated medically).
CABG ¼ coronary artery bypass grafting; CX ¼ circumflex coronary artery;
LAD ¼ left anterior descending coronary artery; PCI ¼ percutaneous coronary
intervention; RCA ¼ right coronary artery; other abbreviations as in Table 3.
FIGURE 3 Head-to-Head Comparison of SPECT and FFRCT
Focal high CAC
n = 30
























Degree of stenosis <70%
n = 63









Degree of stenosis ≥70%
n = 50









Direct comparisons between SPECT and FFRCT are shown for both the entire population and for subgroups of patients with different stenosis
severity. For each cell, the number in first row represents the actual number of patients with the specific combination of SPECT and FFRCT
test results; numbers in second row indicates the number of patients (n [%]) with an FFR value #0.80. MPI ¼ myocardial perfusion imaging;
other abbreviations as in Figure 1.
TABLE 5 Association Between Size of Reversible Perfusion
Defects by SPECT and FFR (n ¼ 139)
Size of Reversible Perfusion Defect Patients FFR #0.80
No reversible perfusion defect 113 34 (30)
Small reversible perfusion defect 7 3 (43)
Moderate reversible perfusion defect 11 8 (73)
Large reversible perfusion defect 8 8 (100)
Values are n or n (%). Test for trend p # 0.001.
SPECT ¼ single-photon emission computed tomography; other abbreviations as
in Table 3.
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1645Overall, there was a significant association be-
tween the per-patient minimum FFRCT value and the
patient-level FFR value (Table 3). Five patients (9%)
had false-negative FFRCT results. The median of the
lowest FFRCT and FFR values in these patients
were 0.82 (range 0.82 to 0.84) and 0.75 (range 0.45
to 0.78), respectively. A significant association
between magnitude of ischemia by SPECT and
patient-level FFR #0.8 was registered (Table 5). Both
the per-patient minimum FFR (s ¼ 0.34; p < 0.0001)
and the FFRCT values (s ¼ 0.29; p < 0.0001) were
negatively associated with the size of RPD.
Six patients with no RPDs had transient ischemic
dilation, of whom 3 patients had an FFR #0.80.
Overall, 34 patients (59%) were misclassified as
normal by SPECT. The median FFR value in these
patients was 0.75 (range 0.43 to 0.80).
DIAGNOSTIC PERFORMANCE OF FFRCT VERSUS
SPECT. Patient diagnostic performances for SPECT
and FFRCT are shown in Figure 4. The per-patient
diagnostic performance of FFRCT compared with
SPECT for identifying ischemia (95% confidence in-
terval [CI]) for sensitivity was 91% (95% CI: 81% to
97%) versus 41% (95% CI: 29% to 55%; p < 0.001); for
specificity was 55% (95% CI: 44% to 66%) versus 86%
(95% CI: 77% to 93%; p < 0.001); for NPV was 90%
(95% CI: 82% to 98%) versus 68% (95% CI: 59% to
77%; p ¼ 0.001); for PPV was 58% (95% CI: 48% to
68%) versus 67% (95% CI: 51% to 82%; p ¼ NS); andfor accuracy was 70% (95% CI: 62% to 77%) versus
68% (95% CI: 60% to 75%; p ¼ NS), respectively. The
sensitivity of FFRCT for predicting ischemia by FFR
remained constantly high over a broad range of pa-
rameters, whereas the sensitivity for SPECT was
consistently low (Table 6).
Patients with an FFR #0.75 (n ¼ 40) were signifi-
cantly more often falsely diagnosed as having a
normal test result by SPECT (n ¼ 19) than by FFRCT
(n ¼ 3; p < 0.001).
PREDICTION OF REVASCULARIZATION BY FFRCT
AND SPECT. The diagnostic performances for pre-
dicting revascularization for SPECT and FFRCT are
shown in Table 7. The sensitivity of FFRCT remained
constantly high and the sensitivity of SPECT consis-
tently low over a broad range of parameters including
the degree of coronary calcification, stenosis severity,
and lesion location (Online Table 1).
FIGURE 4 Patient Diagnostic Performances of FFRCT and SPECT Using FFR as the
Reference Standard
0










100 * * *
* P < 0.001
%
SPECT FFRct
The results of core laboratory FFRCT analysis and SPECT test assessments had no impact on
referral to invasive angiography andwereblinded to the interventionalists.NPV¼negative
predictive value; PPV ¼ positive predictive value; other abbreviations as in Figure 1.
TABLE 6 Patient Diagnostic Sensitivity of FFRCT and SPECT in Subgroups of
Patients With Stable Chest Pain Using FFR as the Reference Standard
FFRCT SPECT
Sensitivity p Value Sensitivity p Value
Male 93 0.609 43 0.773
Female 88 38
Age
#64 yrs 91 1.000 49 0.283
$64 yrs 92 32
Agatston score
#100 94 1.000 55 0.377
100–399 91 33
$400 89 37
Stenosis severity, coronary CTA
40%–69% 100 0.376 27 0.040
70%–90% 88 56
Nonassessable, focal high CAC 91 20
Diseased vessels by ICA
50%, threshold








1 vessel 86 0.312 47 1.000
$2 vessels 100 50
LAD 89 43
Non-LAD 91 1.000 64 0.311
Proximal 87 0.568 51 0.466
Distal 100 33
Values are %.
Abbreviations as in Tables 1 and 3.
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1646False-negative test results were significantly more
frequent by SPECT than by FFRCT assessment, both in
patients undergoing multivessel revascularization:
SPECT (n ¼ 6 [50%]) versus FFRCT (n ¼ 0; p < 0.05),
and in patients treated by single-vessel revasculari-
zation: SPECT (n ¼ 19 [53%]) versus FFRCT (n ¼ 5
[14%]; p < 0.001). In those 6 patients with multivessel
disease and a false negative SPECT result, coronary
artery bypass graft was performed in 4 patients,
triple-vessel percutaneous coronary intervention in 1
patient, and double-vessel PCI in 1 patient. Patient
examples are shown in Figure 5.
DISCUSSION
In this prospective clinical study of symptomatic stable
patients with intermediate range lesions determined
by coronary CTA, no significant differences in
diagnostic accuracy between FFRCT and SPECT were
shown using invasive FFR as the reference standard.
However, significant differences in test sensitivity in
favor of FFRCT for identifying hemodynamically sig-
nificant stenosis and for predicting subsequent revas-
cularization were demonstrated.
Recent landmark trials have demonstrated that an
FFR threshold of 0.80 distinguishes patients and
coronary lesions who will benefit from coronary
revascularization (18,19) from those who will not (20).
Based on these data, FFR has become the gold stan-
dard for making decisions about revascularization in
patients with stable CAD (2,3) and the contemporary
reference standard when evaluating the diagnostic
performance of noninvasive testing strategies in sta-
ble CAD (21,22). Coronary CTA is increasingly used in
the diagnostic work-up of patients suspected of stable
CAD. However, coronary CTA cannot assess the he-
modynamic effect of lesions, especially in interme-
diate range stenosis, where the disconnection
between anatomy and physiology is most profound
(23). Thus, in patients with moderate CAD determined
by coronary CTA, functional testing is now recom-
mended before referral to ICA (2,24). Therefore, the
current study was designed to compare, for the first
time in a prospective fashion, the diagnostic perfor-
mance of FFRCT with that of SPECT for identification
of ischemia, using FFR as the reference standard. The
strategy of frontline coronary CTA testing followed by
functional testing in patients with CAD had 2 main
purposes. The first purpose was to exclude a signifi-
cant number of patients with no or minimal CAD, in
whom prognosis was excellent and thus did not need
further testing (25). The second purpose was to assess
the ICA gate-keeping potentials of the 2 test strategies
in a head-to-head fashion. Thus, this study provides
TABLE 7 Diagnostic Performance of FFRCT and SPECT for
Prediction of FFR-Guided Revascularization in Stable Chest Pain
FFRCT SPECT p Value
Sensitivity 90 (77–97) 48 (33–63) # 0.001
Specificity 50 (39–60) 86 (78–93) # 0.001
PPV 47 (37–58) 64 (48–80) 0.028
NPV 90 (82–98) 77 (69–85) 0.031
Accuracy 63 (55–71) 73 (65–81) 0.067
Values are % (95% confidence interval).
NPV ¼ negative predictive value; PPV ¼ positive predictive value; other ab-
breviations as in Tables 1, 3, and 4.
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1647important evidence for an improved diagnostic
sensitivity of FFRCT relative to established noninva-
sive assessment in patients with stable chest pain and
CAD determined by coronary CTA. The improved
sensitivity of FFRCT was further emphasized by the
subanalysis demonstrating a maintained high sensi-
tivity of FFRCT over a broad range of subgroups.
Differences between FFRCT and SPECT were in
the same range, when considering FFR-guided




















Ischemia test results are shown for 3 patients. Test results for each pat
measured FFR and FFRCT are given as appropriate. All patients had an ab
patients were treated with PCI. From left to right results of coronary CTA
intervention; other abbreviations as in Figures 1 and 2.SPECT performance in the current study is in line
with that in previous studies (17,26,27), in which FFR
was used as the reference standard. The Dan-NICAD
trial (27) and the present study provided an almost
identical sensitivity of SPECT (36% and 41%, respec-
tively) for diagnosing physiologically significant le-
sions. These studies applied a different testing
strategy compared with previous studies, as func-
tional testing was performed exclusively in patients
with moderate CAD, as determined by coronary CTA.
In the prospective PACIFIC trial (26) pre-selection
of patients by coronary CTA was not performed, but
the sensitivity of 56% by SPECT was in the same range
as those in former studies. Moreover, both the PA-
CIFIC trial and the meta-analyses (21,22) indicated a
significantly lower accuracy by SPECT than other
perfusion modalities for diagnosing FFR-defined
ischemia. The low diagnostic sensitivity of SPECT
perfusion imaging may be related to the nonlinear
retention of SPECT tracers, tracer roll-off, at high
coronary flow rates (28). Indeed, the saturation ki-
netics of SPECT tracers may hamper depiction of the





ient are shown in the upper, mid, or lower panel. Exact values of
normal per-patient FFRCT value and normal SPECT scan results; all
, FFRCT, SPECT and ICA/FFR are shown. PCI ¼ percutaneous coronary
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1648induced by adenosine, especially in myocardium
supplied by normal coronary arteries. This disad-
vantage of most nuclear tracers reduces the ability
to diagnose impairment in the vascular response to
adenosine particularly in intermediate range coro-
nary lesions, which not only seem most challenging
but also, numerically, are more frequent than high-
grade lesions in patients with stable chest pain (29).
The diagnostic specificity of SPECT in the PACIFIC
trial (94%) and in the present study (86%) were
higher than both previous studies of SPECT perfor-
mance (30) and significantly higher than for FFRCT in
the present study. The only modest per-patient
specificity of FFRCT in this study may in part be
explained by using the nadir per-vessel FFRCT value
rather than the translesional value (31). Moreover, the
use of pre-coronary CTA nitroglycerine tablets rather
than spray may be associated with a more heteroge-
nous vasodilatory response (32); hence, more falsely
positive FFRCT results compared to invasive FFR.
It should be acknowledged, that the selection of
the patient population by coronary CTA as applied
in the present study is critical for interpretation of
results. Although studies have shown that stable
patients with a normal test result by first-line
perfusion imaging have favorable clinical outcomes
(1,33), it should be acknowledged that visualization
of coronary anatomy was not undertaken in these
patients. In both the present study and the Dan-
NICAD trial, a substantial number of patients
would actually have been undiagnosed by SPECT if
invasive measurements had not been undertaken.
Accordingly, 2 recently published studies, a meta-
analysis (34) and a substudy of the PROMISE
(Prospective Multicenter Imaging Study for Evalua-
tion of Chest Pain) trial (35) comparing outcomes
in patients tested with coronary CTA versus func-
tional testing strategies demonstrated a significantly
lower incidence of major adverse cardiac events
following anatomic assessment by coronary CTA.
These data indicate that a normal perfusion scan
cannot automatically be taken as a marker for
normal coronary arteries, and importantly, the
overall cohort prognosis cannot inevitably be trans-
lated into those patients who are misclassified as
normal by perfusion imaging. However, more
studies are needed to confirm the present results
and ultimately to assess the influence of a first-line
testing strategy using FFRCT instead of SPECT on
clinical outcomes.
STUDY LIMITATIONS. Patients in this study were
included at 1 center. Although the cohort reflects
consecutive patients in whom frontline coronary CTAtesting was relevant in contemporary practice, it may
be speculated that core laboratory adjudication of
coronary CTA and FFR tracings would have been
valuable. However, off-line core laboratory test
adjudication in this trial was restricted to the blinded
analyses of the 2 modalities being evaluated in order
to mirror as much as possible real-world clinical
practice. The time span between coronary CTA and
following per-protocol invasive study modalities was
24 days, but it seems unlikely that any significant
changes in the atherosclerotic disease occurred be-
tween tests within this short time frame.
Referring patients who were eligible for coronary
CTA testing directly to SPECT might have biased the
results. However, this study was conducted in
consecutive patients at 1 single center with strictly
defined algorithms for ruling out coronary artery
disease by first-line coronary CTA; thus, we do not
believe that this factor influenced the results of this
study. This study only applied to patients in whom
coronary CTA testing was appropriate. In addition,
FFRCT cannot be calculated in all patients, especially
in the event of deteriorated CT image quality (10).
However, in this and in recent studies (12) from
clinical practice, FFRCT could be performed in most
patients.
Finally, it should be noted that sensitivity analyses
in subgroups should be interpreted with caution, as
no sample size estimations for performing these an-
alyses were done.
CONCLUSIONS
This prospective study of patients with intermediate
coronary lesions determined by coronary CTA did not
showanydifference in the diagnostic accuracy of FFRCT
and SPECT when using invasive FFR as the reference
standard. However, the diagnostic sensitivity for
predicting FFR-guided revascularization by FFRCT
was superior to SPECT. Future studies are needed in
order to clarify, whether the reported improvement
in diagnostic sensitivity by FFRCT over SPECT can
be translated into improved clinical outcomes.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Coronary
CTA is increasingly used as the first-line test in patients
suspected of stable CAD. However, patients with inter-
mediate range stenosis often require further testing, and
the optimal downstream management strategy in such
patients is unclear. We prospectively evaluated the
diagnostic performance of FFRCT and myocardial perfu-
sion imaging by SPECT in symptomatic patients with in-
termediate range coronary stenosis by using measured
FFR as the reference standard. Observers performing FFR
were blinded to the results of FFRCT and SPECT. We found
a comparable diagnostic accuracy of the two non-invasive
testing strategies. However, the diagnostic sensitivity for
assessing hemodynamically significant coronary stenosis
was significantly higher for FFRCT compared to SPECT
perfusion imaging.
TRANSLATIONAL OUTLOOK: The current study ad-
vocates, as a first-line strategy, coronary CTA for ruling
out the existence of CAD and selective FFRCT-testing in
patients with intermediate range lesions as gatekeeping
to invasive coronary angiography. Further large scale
studies are needed to assess cost efficiency and safety of
the reported first-line/2-step coronary CTA strategy
versus conventional myocardial perfusion imaging
strategies.
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